12:00 AM
 | 
Jan 28, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Tenofovir alafenamide fumarate: Phase III started

Gilead began the double-blind Phase III Study 104 trial to compare once-daily TAF/elvitegravir/cobicistat/emtricitabine vs. Gilead's Stribild elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate for 96 weeks in about 840 treatment-naïve HIV-1 infected adults with viral load >=1,000 copies/mL. The trial includes an open-label rollover extension. Gilead said it will begin the similar Phase III Study 111 trial of the product later this quarter.

Gilead markets Stribild, nucleoside...

Read the full 309 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >